3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
2
Skin Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Autoimmune Diseases
1
Interventions
Doxorubicin
13
Gemcitabine
10
Cyclophosphamide
10
pazopanib
8
Filgrastim
8
Radiotherapy
7
Ifosfamide
7
Cisplatin
7
Irinotecan
6
Docetaxel
6
Radiation
5
Granulocyte Colony-Stimulating Factor
5
Etoposide
5
Trabectedin
4
Magnetic Resonance Spectroscopy
4
Celecoxib
4
Busulfan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
temsirolimus
3
sargramostim
3
pembrolizumab
3
X-Rays
3
Sirolimus
3
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Neoadjuvant Therapy
3
Leucovorin
3
Dexrazoxane
3
Cryosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Sarcoma
×
Immunotherapy
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled